CoChat

A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity

Open access
Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., Hofmann, J., Kristinsson, H., Kullberg, J., Ladinger, A., Lagler, F. B., Lidström, M., Manell, H., Meirik, M., Mörwald, K., Roomp, K., Schneider, R., Vilén, H., Widhalm, K., Zsoldos, F., Bergsten, P. · 2020 · Pediatric Obesity
Cited by 78

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon‐like‐peptide‐1 (GLP‐1) receptor agonist could be a treatment option for adolescent obesity. Objective: To investigate the effect of exenatide extended release on body mass index (BMI)‐SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. Methods: Six‐month, randomized, double‐blinded, parallel, placebo‐controlled clinical trial in patients (n = 44, 10‐18 years, females n = 22) with BMI‐SDS > 2.0 or age‐adapted‐BMI > 30 kg/m 2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention. Results: Exenatide reduced (P < .05) BMI‐SDS (−0.09; −0.18, 0.00), % BMI 95th percentile (−2.9%; −5.4, −0.3), weight (−3 kg; −5.8, −0.1), waist circumference (−3.2 cm; −5.8, −0.7), subcutaneous adipose tissue (−552 cm 3; −989, −114), 2‐hour‐glucose during OGTT (−15.3 mg/dL; −27.5, −3.1), total cholesterol (11.6 mg/dL; −21.7, −1.5), and BMI (−0.83 kg/m 2; −1.68, 0.01) without significant change in liver fat content (−1.36; −3.12, 0.4; P = .06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide‐treated patients. Conclusions: Treatment of adolescents with severe obesity with extended‐release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ijpo.12624

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 78

Metadata

Authors
Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., Hofmann, J., Kristinsson, H., Kullberg, J., Ladinger, A., Lagler, F. B., Lidström, M., Manell, H., Meirik, M., Mörwald, K., Roomp, K., Schneider, R., Vilén, H., Widhalm, K., Zsoldos, F., & Bergsten, P.
Venue
Pediatric Obesity
Publisher
Wiley
Published
2020-02-16
Volume
15
Issue
7
Pages
e12624-e12624
ISSN
  • 2047-6302 (ISSN-L)
  • 2047-6310
OpenAlex
W3005805429
Cited by
78
References
7
FWCI
4.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. https://app.cochat.ai/papers/10.1111/ijpo.12624
The paper
Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., Hofmann, J., Kristinsson, H., Kullberg, J., Ladinger, A., Lagler, F. B., Lidström, M., Manell, H., Meirik, M., Mörwald, K., . . . Bergsten, P. (2020). A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity. Pediatric Obesity. https://doi.org/10.1111/ijpo.12624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.